- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01257503
Homeopathic Cold Remedy for Children Study
December 31, 2014 updated by: James Taylor, University of Washington
Randomized Controlled Trial of a Homeopathic Cold Remedy for Children
A randomized controlled trial of a commercially available homeopathic cold remedy will be conducted.
A total of 400 children, 2-5 years old, diagnosed with an upper respiratory tract infection will be randomized to receive either the homeopathic remedy or placebo.
Parents of study children will administer 5 ml of the study medication up to 6 times per day as needed to treat cold symptoms.
One hour after giving a dose the parent will rate change in symptoms (for up to the first 10 doses).
In addition, parents will rate their child's overall symptom severity and functional status over the first 3 days of the cold.
It is postulated that children receiving the active homeopathic remedy will have better symptom relief and that their symptom severity and functional status will improve more rapidly than those receiving placebo.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
263
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98105
- University of Washington Medical Center- Roosevelt Pediatric Care Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
2 years to 5 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- clinical diagnosis of upper respiratory tract infection
- duration of symptoms < 7 days
- Parent who speaks English
Exclusion Criteria:
- history of asthma
- on any prescribed medication
- prescribed any medication other than acetaminophen or ibuprofen at index visit
- use of homeopathic remedy within 48 hours of index visit
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Homeopathic cold remedy
5 ml of homeopathic cold remedy given by mouth up to 6 times per day as needed for cold symptoms
|
5 ml PO q4h prn cold symptoms
|
Placebo Comparator: placebo
5 ml of placebo given by mouth up to 6 times per day as needed for cold symptoms
|
liquid made to look like the active homeopathic remedy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Severity of Cold Symptoms
Time Frame: Parents assessed change in symptom 1 hour after a dose of study medication
|
Parents measured change in runny nose, cough, nasal congestion and sneezing severity one hour after administering a dose of study medication up to the first 10 doses of study medication.
Change in symptom rated from 0 to 6, with 0 indicative of the symptom being much worse and 6 indicative of the symptom being much improved.
The unit of analysis for each outcome was doses of medication.
Each participant could contribute data on 0 - 10 doses.
|
Parents assessed change in symptom 1 hour after a dose of study medication
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Non-specific Symptoms
Time Frame: Parents assessed change in symptom 1 hour after dose of study medication
|
Parents measured change in severity of irritability, lethargy, fussiness, and appetite one hour after administering a dose of study medication up to the first 10 doses of study medication.
Change in symptom rated from 0 to 6, with 0 indicative of the symptom being much worse and 6 indicative of the symptom being much improved.
The unit of analysis for each outcome was doses of medication.
Each participant could contribute data on 0 - 10 doses.
|
Parents assessed change in symptom 1 hour after dose of study medication
|
Functional Status
Time Frame: 10 days
|
Change in functional status of child during the 7-10 days after the index visit for an upper respiratory tract infection.
Parents rated 5 activities (vigorous activity, activities that require concentration, activities with family or friends, appetite and sleep) daily for 3 days in their child and again at the 7-10 day follow-up.
Functional status scores range from 0 to 15, with higher scores indicative of better functional status.
|
10 days
|
Health Status
Time Frame: 10 days
|
Change in health status of child during the 7-10 days after the index visit for an upper respiratory tract infection.
Parents rated health status on 1-10 scale with 1 indicating perfect health and 10 indicating very sick.
Health status rated on first 3 days of study and again at the 7-10 day follow-up
|
10 days
|
Overall Symptom Severity
Time Frame: 10 days
|
Change in cold symptoms of child during the 7-10 days after the index visit for an upper respiratory tract infection.
Parents assessed severity of runny nose, cough, sneeze and congestion in their child using a 0-3 scale for each symptom, 0=none to 3= severe.
Cold score is sum of scores for each symptom.
Parents assessed cold score twice daily on study days 1-3 and at the 7-10 day follow-up
|
10 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2010
Primary Completion (Actual)
August 1, 2013
Study Completion (Actual)
December 1, 2013
Study Registration Dates
First Submitted
December 8, 2010
First Submitted That Met QC Criteria
December 8, 2010
First Posted (Estimate)
December 9, 2010
Study Record Updates
Last Update Posted (Estimate)
January 14, 2015
Last Update Submitted That Met QC Criteria
December 31, 2014
Last Verified
December 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 39489-D
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Upper Respiratory Tract Infections
-
University of WashingtonNational Center for Complementary and Integrative Health (NCCIH)WithdrawnUpper Respiratory Infections
-
University of UtahCompletedUpper Respiratory Infections
-
NovartisNovartis Consumer HealthCompleted
-
Stephen J. Teach, MD, MPHNational Institute of Allergy and Infectious Diseases (NIAID)RecruitingAsthma in Children | Atopy | Viral Upper Respiratory InfectionUnited States
-
BioHealth Technologies Inc.CompletedUpper Respiratory InfectionsUnited States
-
Thomas ErbCompletedUpper Respiratory InfectionsSwitzerland
-
Société des Produits Nestlé (SPN)Completed
-
The Archer-Daniels-Midland CompanyAtlantia Food Clinical TrialsRecruitingUpper Respiratory Tract Infections | Upper Resp Tract InfectionIreland
-
Valenta Pharm JSCCompletedInfluenza | Viral Respiratory Infection | Acute Viral Upper Respiratory InfectionsRussian Federation
Clinical Trials on Hyland's Cold 'n Cough 4 kids
-
University of WashingtonStandard Homeopathic CompanyCompleted
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingT Acute Lymphoblastic Leukemia | T Lymphoblastic LymphomaUnited States